Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FHTX
STRONG SELLFoghorn Therapeutics Inc. · Healthcare · United States · $285M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics targeting the chromatin regulatory system for cancer and other serious diseases. The company's proprietary Gene Traffic Control® platform identifies and validates targets within this system, offering a differentiated approach to drug discovery. Foghorn is a niche player in epigenetics, aiming to unlock new treatment modalities for difficult-to-treat diseases through precision medicine.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 19.2M | 34.2M | 22.6M | 30.9M | 17.1% | 28.2M | 25.8M | 37.4M | 10.0% |
| EPS | -2.73 | -2.62 | -2.34 | -1.58 | -1.18 | — | -1.17 | -1.06 | -1.10 | — |
| Shares | — | 41.8M | 42.3M | 55.6M | 56.7M | +35.5% | 58.7M | — | — | — |
| Debt | — | 51.5M | 45.1M | 37.1M | 41.3M | -7.1% | 42.0M | — | — | — |
| Equity | — | 0.1M | -77.2M | -45.5M | -108.5M | — | — | — | — | — |
| Op CF | — | 193.6M | -118.1M | -100.4M | -86.1M | — | -87.4M | — | — | — |
| Inv CF | — | -244.3M | 144.4M | -29.9M | 112.0M | — | — | — | — | — |
| Fin CF | — | 1.8M | 1.8M | 105.4M | 1.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FHTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FHTX | Foghorn Therapeutics Inc.(you) | $285M | 6 | STRONG SELL |
| LCTX | Lineage Cell Therapeutics, Inc. | $257M | 8 | STRONG SELL |
| NMRA | Neumora Therapeutics, Inc. | $276M | 10 | STRONG SELL |
| TTRX | Turn Therapeutics Inc. | $254M | 10 | STRONG SELL |
| UPB | Upstream Bio, Inc. | $349M | 8 | STRONG SELL |
| CMPX | Compass Therapeutics, Inc. | $373M | 7 | STRONG SELL |
| INDP | Indaptus Therapeutics, Inc. | $348M | 8 | STRONG SELL |
| LYEL | Lyell Immunopharma, Inc. | $309M | 2 | STRONG SELL |
| TRDA | Entrada Therapeutics, Inc. | $227M | 8 | STRONG SELL |
| OTLK | Outlook Therapeutics, Inc. | $263M | 11 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%